COST-EFFECTIVENESS OF RIVAROXABAN FOR THE TREATMENT OF PULMONARY EMBOLISM IN CANADA

被引：1
|
作者：
Levac, B. [1 ]
Marrie, J. [1 ]
Chin, W. [2 ]
Hassan, F. [3 ]
Bamber, L. [4 ]
McLeod, E. J. [3 ]
机构：
[1] Bayer Inc, Toronto, ON, Canada
[2] ILEX Consulting Inc, Toronto, ON, Canada
[3] IMS Hlth, London, England
[4] Bayer Healthcare, Leverkusen, Germany
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.684
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV90
引用
收藏
页码：A117 / A118
页数：2
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece
    George Gourzoulidis
    Georgia Kourlaba
    John Kakisis
    Mitiadis Matsagkas
    George Giannakoulas
    Konstantinos I. Gourgoulianis
    Theodoros Vassilakopoulos
    Nikos Maniadakis
    Clinical Drug Investigation, 2017, 37 : 833 - 844
  • [2] Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece
    Gourzoulidis, George
    Kourlaba, Georgia
    Kakisis, John
    Matsagkas, Mitiadis
    Giannakoulas, George
    Gourgoulianis, Konstantinos I.
    Vassilakopoulos, Theodoros
    Maniadakis, Nikos
    CLINICAL DRUG INVESTIGATION, 2017, 37 (09) : 833 - 844
  • [3] Cost-effectiveness of rivaroxaban for the treatment of pulmonary embolism and secondary prevention of venous thromboembolism - a UK perspective
    McLeod, E.
    Guillermin, A.
    Hudson, R.
    Bamber, L.
    Muston, D.
    Lensing, A. W. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 90 - 90
  • [4] Cost-effectiveness of pulmonary embolism diagnosis
    Hull, RD
    Feldstein, W
    Stein, PD
    Pineo, GF
    ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (01) : 68 - 72
  • [5] Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism
    Perlroth, Daniella J.
    Sanders, Gillian D.
    Gould, Michael K.
    ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (01) : 74 - 80
  • [6] COST EFFECTIVENESS ANALYSIS OF RIVAROXABAN FOR TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN GREECE
    Gourzoulidis, G.
    Kourlaba, G.
    Kakisis, J.
    Matsagkas, M.
    Giannakoulas, G.
    Gourgoulianis, K.
    Vassilakopoulos, T.
    Arzoumanidou, D.
    Maniadakis, N.
    VALUE IN HEALTH, 2016, 19 (07) : A554 - A554
  • [7] Diagnosis of pulmonary embolism: A cost-effectiveness analysis
    Doyle, NM
    Ramirez, MM
    Mastrobattista, JM
    Monga, M
    Wagner, LK
    Gardner, MO
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 191 (03) : 1019 - 1023
  • [8] Cost-effectiveness of pulmonary embolism diagnosis - In reply
    Hull, R
    Pineo, G
    Stein, P
    ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (14) : 1589 - 1589
  • [9] COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH COMBINED LOW MOLECULAR WEIGHT HEPARIN/VITAMIN K ANTAGONIST FOR THE TREATMENT OF PULMONARY EMBOLISM IN CHINA
    Feng, Y.
    Yang, L.
    Wu, J.
    VALUE IN HEALTH, 2018, 21 : S62 - S62
  • [10] Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada Comparative efficacy and cost-effectiveness
    Kansal, Anuraag R.
    Sharma, Michael
    Bradley-Kennedy, Carole
    Clemens, Andreas
    Monz, Brigitta U.
    Peng, Siyang
    Roskell, Neil
    Sorensen, Sonja V.
    THROMBOSIS AND HAEMOSTASIS, 2012, 108 (04) : 672 - 682
12345